|Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study|
|Pan, Changyu1; Han, Ping4; Ji, Linong2; Ji, Qiuhe5; Lu, Juming1; Lin, Jing3; Liu, Jie6; Su, Benli7; Shi, Jingmei8; Wang, Penghua9|
|关键词||body mass index body weight insulin detemir type 2 diabetes mellitus|
|刊名||JOURNAL OF DIABETES|
|WOS标题词||Science & Technology|
|类目[WOS]||Endocrinology & Metabolism|
|研究领域[WOS]||Endocrinology & Metabolism|
|关键词[WOS]||IMPROVES GLYCEMIC CONTROL ; NPH INSULIN ; NAIVE PATIENTS ; BODY-WEIGHT ; FOOD-INTAKE ; THERAPY ; GAIN ; MELLITUS ; OVERWEIGHT ; GLARGINE|
BackgroundThe present subanalysis of the Study of Once Daily Levemir (SOLVE) study was to evaluate the safety and efficacy of once-daily insulin detemir as add-on to oral antidiabetic drugs (OADs) in Chinese type 2 diabetes patients according to body mass index in a real-life setting.
MethodsIn all, 3272 eligible patients who were treated with diet, exercise, and one or more OAD were prescribed once-daily insulin detemir by their physician according to routine clinical practice and were followed-up for 24 weeks. The incidence of serious adverse reactions (SADRs), including major hypoglycemia, was the primary endpoint. Subanalyses were performed on patients in the following BMI groups: normal weight (BMI<25kg/m(2)); overweight (25BMI<30kg/m(2)); and obese (BMI30kg/m(2)).
ResultsNo SADRs were reported during the study. Significant improvements in glycemic levels were observed in all subgroups. For normal weight, overweight, and obese patients, the mean change in HbA1c (%/[mmol/mol]) was -1.26/-14, -1.09/-12, and -1.06/-12, respectively. The mean change in fasting plasma glucose in normal weight, overweight, and obese patients was -2.77, -2.57, and -2.71mmol/L, respectively. Slight weight gain (0.25kg), slight weight loss (-0.36kg), and weight loss (-1.32kg) were observed in the normal weight, overweight, and obese patients, respectively (P<0.001). Linear regression analysis revealed a negative relationship between weight change and baseline BMI (slope=-0.16; P<0.001).
ConclusionsOnce-daily insulin detemir as add-on to OADs in Chinese patients with type 2 diabetes showed effective glycemic control and a low risk of hypoglycemia. Weight-neutral effects were observed in different BMI subgroups.
|作者单位||1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China|
2.Beijing Huaxin Hosp, Beijing, Peoples R China
3.4th Mil Med Univ, Xijing Hosp, Xian, Peoples R China
4.Shanxi Prov Peoples Hosp, Taiyuan, Peoples R China
5.Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China
6.Yuncheng Tongde Hosp, Yuncheng, Peoples R China
7.Tianjin Med Univ, Metab Dis Hosp, Tianjin, Peoples R China
8.Chinese Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China
9.China Med Univ, Shengjing Hosp, Shenyang 110001, Peoples R China
|Pan, Changyu,Han, Ping,Ji, Linong,et al. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study[J]. JOURNAL OF DIABETES,2015,7(2):222-230.|
|APA||Pan, Changyu.,Han, Ping.,Ji, Linong.,Ji, Qiuhe.,Lu, Juming.,...&Wang, Penghua.(2015).Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study.JOURNAL OF DIABETES,7(2),222-230.|
|MLA||Pan, Changyu,et al."Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: Subgroup analysis of the SOLVE study".JOURNAL OF DIABETES 7.2(2015):222-230.|